Comparative use of urinary and recombinant human chorionic gonadotropins in women.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing comparative trials without systematic review or meta-analytic methodology.
PubMed 15511131 · doi:10.2165/00024677-200403060-00005
What was done
This narrative review evaluated the pharmacokinetic, pharmacodynamic, efficacy, and safety profiles comparing recombinant human chorionic gonadotropin (r-hCG) with urinary-derived human chorionic gonadotropin (u-hCG) preparations used to trigger final oocyte maturation in anovulatory women.
What was found
The abstract reports no numerical data or statistical effect sizes. Qualitatively, it states that r-hCG demonstrates pharmacokinetic and pharmacodynamic profiles similar to u-hCG, achieves at least equivalent efficacy in reproducing the mid-cycle LH surge follicular events, supports a better luteal phase hormonal environment, and exhibits superior overall tolerability and safety with fewer local and immunologic adverse reactions.
Why it matters
Recombinant hCG provides high purity and batch-to-batch consistency, allowing clinicians to manage ovulation induction protocols entirely with recombinant gonadotropin products.
Limits
The abstract provides no quantitative data, sample sizes, confidence intervals, or details regarding the search strategy. As a narrative review, it carries inherent risk of selective reporting and lacks meta-analytic pooling.
Cited by
- supports Commercial human chorionic gonadotropin (hCG) is purified from the urine of pregnant women.